Alector (id:7964 ALEC)
3.94 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:54:42 PM)
Exchange closed, opens in 20 hours 35 minutes
About Alector
Market Capitalization 385.85M
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
| Headquarters (address) |
131 Oyster Point Boulevard South San Francisco 94080 CA United States |
| Phone | 415 231 5660 |
| Website | https://www.alector.com |
| Employees | 244 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ALEC |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.49 - 8.90 |
| Market Capitalization | 385.85M |
| P/E trailing | -2.53 |
| P/E forward | -2.66 |
| Price/Sale | 6.27 |
| Price/Book | 3.25 |
| Beta | 0.657 |
| EPS | -1.71 |
| EPS United States (ID:6, base:3402) | 24.22 |